Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix

After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences’ (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares

https://bit.ly/2LMioJs